Iron Chelation Therapy in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic option...
Saved in:
Main Authors: | Emanuela Messa, Daniela Cilloni, Giuseppe Saglio |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2010/756289 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome
by: Maha A. Badawi, et al.
Published: (2010-01-01) -
Iron Chelators in Treatment of Iron Overload
by: Sarina Entezari, et al.
Published: (2022-01-01) -
Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome
by: Andrea L. Merrill, et al.
Published: (2011-01-01) -
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
by: Zoe King, et al.
Published: (2025-03-01) -
Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
by: Yasuo Miura, et al.
Published: (2010-01-01)